203 related articles for article (PubMed ID: 9781932)
1. Saterinone, dobutamine, and sodium nitroprusside: comparison of cardiovascular profiles in patients with congestive heart failure.
Kieback AG; Iven H; Stolzenburg K; Baumann G
J Cardiovasc Pharmacol; 1998 Oct; 32(4):629-36. PubMed ID: 9781932
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and hemodynamic effects of the phosphodiesterase III inhibitor saterinone in patients with chronic heart failure.
Kieback AG; Iven H; Stolzenburg K; Eichner E; Ruckdeschel W; Baumann G
Int J Cardiol; 2003 Oct; 91(2-3):201-8. PubMed ID: 14559131
[TBL] [Abstract][Full Text] [Related]
3. Hemodynamic and autonomic effects of intravenous saterinone in patients with chronic heart failure.
Szabó BM; van Veldhuisen DJ; van Dijk RB; Lahiri A; Mitrovic V; Stolzenburg K; Brouwer J; Lie KI
J Cardiovasc Pharmacol; 1997 May; 29(5):618-23. PubMed ID: 9213204
[TBL] [Abstract][Full Text] [Related]
4. [The hemodynamic effects of the combination of milrinone in heart failure refractory to treatment with dopamine, dobutamine and/or nitroprusside].
Domínguez de Rozas JM; Guindo Soldevila J; Rodríguez Font E; Martínez Vílchez R
Rev Esp Cardiol; 1994 Oct; 47(10):682-6. PubMed ID: 7991922
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular effects of forskolin (HL 362) in patients with idiopathic congestive cardiomyopathy--a comparative study with dobutamine and sodium nitroprusside.
Baumann G; Felix S; Sattelberger U; Klein G
J Cardiovasc Pharmacol; 1990 Jul; 16(1):93-100. PubMed ID: 1696672
[TBL] [Abstract][Full Text] [Related]
6. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside.
Jaski BE; Fifer MA; Wright RF; Braunwald E; Colucci WS
J Clin Invest; 1985 Feb; 75(2):643-9. PubMed ID: 3973022
[TBL] [Abstract][Full Text] [Related]
7. Dobutamine and nitroprusside infusion in patients with severe congestive heart failure: hemodynamic improvement by discordant effects on mitral regurgitation, left atrial function, and ventricular function.
Capomolla S; Pozzoli M; Opasich C; Febo O; Riccardi G; Salvucci F; Maestri R; Sisti M; Cobelli F; Tavazzi L
Am Heart J; 1997 Dec; 134(6):1089-98. PubMed ID: 9424070
[TBL] [Abstract][Full Text] [Related]
8. Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness.
Colucci WS; Wright RF; Jaski BE; Fifer MA; Braunwald E
Circulation; 1986 Mar; 73(3 Pt 2):III175-83. PubMed ID: 3510774
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects on hemodynamics of enoximone (MDL 17,043), dobutamine and nitroprusside in severe congestive heart failure.
Installé E; Gonzalez M; Jacquemart JL; Collard P; Roulette F; Pourbaix S; Tremouroux J
Am J Cardiol; 1987 Aug; 60(5):46C-52C. PubMed ID: 2956868
[TBL] [Abstract][Full Text] [Related]
10. Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure.
Monrad ES; Baim DS; Smith HS; Lanoue AS
Circulation; 1986 Mar; 73(3 Pt 2):III168-74. PubMed ID: 3510773
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. Milrinone-Dobutamine Study Group.
Karlsberg RP; DeWood MA; DeMaria AN; Berk MR; Lasher KP
Clin Cardiol; 1996 Jan; 19(1):21-30. PubMed ID: 8903534
[TBL] [Abstract][Full Text] [Related]
12. CI-930, a new cardiotonic and vasodilating agent: hemodynamic comparison to dobutamine and long-term clinical effects.
Mancini D; Keren G; Sonnenblick EH; LeJemtel TH
Am Heart J; 1988 Oct; 116(4):1008-16. PubMed ID: 3177174
[TBL] [Abstract][Full Text] [Related]
13. Hemodynamic advantage of combined administration of oral ibopamine and nitroprusside in patients with ischemic and idiopathic congestive cardiomyopathy.
Dei Cas L; Fappani A; Riva S; Metra M; Cicogna R; Manca C; Visioli O
Clin Cardiol; 1985 Aug; 8(8):427-32. PubMed ID: 4028536
[TBL] [Abstract][Full Text] [Related]
14. Hemodynamic effect of oral TA-064 after dobutamine in congestive heart failure.
Takatsu Y; Yui Y; Hattori R; Sakaguchi K; Susawa T; Yui N; Kawai C
Jpn Circ J; 1987 Jun; 51(6):611-6. PubMed ID: 3312701
[TBL] [Abstract][Full Text] [Related]
15. Comparison between the positive inotropic effects of enoximone, a cardiac phosphodiesterase III inhibitor, and dobutamine in patients with moderate to severe congestive heart failure. A study using the end-systolic pressure-volume relationship method.
Installe E; De Coster P; Gonzalez M; Brichant C; Lessire H; Cauwe F
Eur Heart J; 1991 Sep; 12(9):985-93. PubMed ID: 1834466
[TBL] [Abstract][Full Text] [Related]
16. Degree of external force to the left ventricle determines hemodynamic response to nitroprusside in failing hearts: comparison with the response to dobutamine.
Yamamoto K; Masuyama T; Nagano R; Doi Y; Naito J; Mano T; Kondo H; Hori M; Kamada T
J Cardiovasc Pharmacol; 1995 Oct; 26(4):596-602. PubMed ID: 8569221
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase III inhibition or adrenoreceptor stimulation: milrinone as an alternative to dobutamine in the treatment of severe heart failure.
Mager G; Klocke RK; Kux A; Höpp HW; Hilger HH
Am Heart J; 1991 Jun; 121(6 Pt 2):1974-83. PubMed ID: 1852090
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of combined dopamine and nitroprusside versus dobutamine and nitroprusside infusions for computer-controlled management of low-output cardiac failure after open heart surgery.
Pomer S; Elert O; Sarai K; Satter P
Int J Clin Pharmacol Ther Toxicol; 1986 Feb; 24(2):77-81. PubMed ID: 3957495
[TBL] [Abstract][Full Text] [Related]
19. Combined hemodynamic and scintigraphic assessment of piroximone (MDL 19,205) and comparison with dobutamine and nitroprusside.
Massie BM; Cornyn J; Topic N; Loge D; Podolin RA
Am J Cardiol; 1987 Sep; 60(8):647-53. PubMed ID: 3661429
[TBL] [Abstract][Full Text] [Related]
20. Comparative hemodynamic effects of intravenous dobutamine and dibutyryl cyclic AMP, a new inotropic agent, in severe congestive heart failure.
Miyagi Y; Sasayama S; Nakajima H; Fujita M; Asanoi H
J Cardiovasc Pharmacol; 1990 Jan; 15(1):138-43. PubMed ID: 1688971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
